Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2006

01-07-2006 | Phase I Studies

Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

Authors: Thomas Olencki, Sareena Malhi, Tarek Mekhail, Robert Dreicer, Paul Elson, Laura Wood, Ronald M. Bukowski

Published in: Investigational New Drugs | Issue 4/2006

Login to get access
Metadata
Title
Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma
Authors
Thomas Olencki
Sareena Malhi
Tarek Mekhail
Robert Dreicer
Paul Elson
Laura Wood
Ronald M. Bukowski
Publication date
01-07-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-5211-z

Other articles of this Issue 4/2006

Investigational New Drugs 4/2006 Go to the issue

Phase II Studies

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

Phase I Studies

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

Phase I Studies

A phase I study of flavopiridol and docetaxel

Phase II Studies

A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Phase II Studies

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

Phase I Studies

A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits